AstraZeneca PLC (AZN), Bristol-Myers Squibb Company (BMY) Join Forces in $7 Billion Deal for Amylin Pharmaceuticals, Inc. (AMLN)  
7/2/2012 6:41:00 AM

Bristol-Myers Squibb Co. (NASDAQ:BMY) and AstraZeneca plc (NYSE:AZN) have teamed up to execute a uniquely structured takeover of diabetes firm Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) for a total value of $7 billion - the fourth and largest billion-dollar-plus deal of 2012.

Amylin's assets include GLP-1 agonists Byetta (exenatide) and its extended release equivalent Bydureon, Metreleptin, and Symlin (pramlintide acetate) and has been on the market for acquisition for some time.